Free Trial

MetLife (MET) Stock Price, News & Analysis

$76.00
+0.68 (+0.90%)
(As of 07/26/2024 ET)
Today's Range
$75.09
$76.40
50-Day Range
$68.55
$76.18
52-Week Range
$57.91
$76.90
Volume
2.39 million shs
Average Volume
3.33 million shs
Market Capitalization
$54.05 billion
P/E Ratio
26.12
Dividend Yield
2.87%
Price Target
$81.08

MetLife MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
6.7% Upside
$81.08 Price Target
Short Interest
Healthy
1.30% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.65mentions of MetLife in the last 14 days
Based on 21 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
13.39%
From $8.59 to $9.74 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.95 out of 5 stars

Finance Sector

13th out of 898 stocks

Life Insurance Industry

4th out of 21 stocks

MET stock logo

About MetLife Stock (NYSE:MET)

MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was incorporated in 1999 and is based in New York, New York.

MET Stock Price History

MET Stock News Headlines

Citigroup Raises MetLife (NYSE:MET) Price Target to $89.00
We recommended Nvidia in 2016, now we’re recommending this…
The AI boom is just getting started. And the real wealth has still to be made…
This MetLife Insider Reduced Their Stake By 32%
We recommended Nvidia in 2016, now we’re recommending this…
The AI boom is just getting started. And the real wealth has still to be made…
MetLife (MET) Set to Announce Quarterly Earnings on Wednesday
3 Rock-Solid Income Machines to Hold for Decades
See More Headlines
Receive MET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MetLife and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2024
Ex-Dividend for 6/11 Dividend
5/06/2024
Dividend Payable
6/11/2024
Today
7/26/2024
Next Earnings (Confirmed)
7/31/2024
Ex-Dividend for 9/10 Dividend
8/06/2024
Dividend Payable
9/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Finance
Industry
Life insurance
Sub-Industry
Life & Health Insurance
CUSIP
59156R10
Employees
45,000
Year Founded
1868

Price Target and Rating

Average Stock Price Target
$81.08
High Stock Price Target
$89.00
Low Stock Price Target
$71.00
Potential Upside/Downside
+6.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

Net Income
$1.58 billion
Pretax Margin
4.37%

Debt

Sales & Book Value

Annual Sales
$66.91 billion
Cash Flow
$6.85 per share
Book Value
$40.87 per share

Miscellaneous

Free Float
708,919,000
Market Cap
$54.05 billion
Optionable
Optionable
Beta
1.11

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Should I Buy MetLife Stock? MET Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in MetLife, Inc.:

  • MetLife's stock price has been consistently above its 50-day and 200-day moving averages, indicating positive momentum in the market.
  • MetLife has a history of increasing dividends, providing investors with a steady income stream.
  • Analysts have given MetLife a "Moderate Buy" rating with a consensus price target of $79.08, suggesting potential for stock price appreciation.
  • MetLife's share buyback plan signals confidence from the company's leadership in the stock's undervaluation, potentially leading to increased shareholder value.
  • MetLife's diverse range of financial services globally positions it well to capitalize on various market conditions and opportunities.

Cons

Investors should be bearish about investing in MetLife, Inc. for these reasons:

  • MetLife's payout ratio of 74.91% indicates a significant portion of earnings being distributed as dividends, potentially limiting reinvestment for growth.
  • Recent fluctuations in revenue compared to analysts' estimates may raise concerns about the company's ability to consistently meet expectations.
  • While the stock has received positive ratings, any unforeseen market changes or economic downturns could impact MetLife's performance.
  • The company's net margin of 3.50% suggests relatively low profitability compared to industry peers, which could affect investor returns.
  • Investors should consider the impact of regulatory changes in the financial services sector on MetLife's operations and profitability.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, July 5, 2024. Please send any questions or comments about these MetLife pros and cons to contact@marketbeat.com.

MET Stock Analysis - Frequently Asked Questions

How have MET shares performed this year?

MetLife's stock was trading at $66.13 at the start of the year. Since then, MET shares have increased by 14.9% and is now trading at $76.00.
View the best growth stocks for 2024 here
.

How were MetLife's earnings last quarter?

MetLife, Inc. (NYSE:MET) announced its quarterly earnings results on Wednesday, May, 1st. The financial services provider reported $1.83 EPS for the quarter, meeting analysts' consensus estimates of $1.83. The firm's quarterly revenue was up 5.5% on a year-over-year basis.
Read the conference call transcript
.

Is MetLife doing a stock buyback?

MetLife's board authorized a share buyback plan on Wednesday, May 1st 2024, which allows the company to repurchase $3,000,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 6% of its shares through open market purchases. Shares buyback plans are often a sign that the company's management believes its stock is undervalued.

What is Michel Khalaf's approval rating as MetLife's CEO?

308 employees have rated MetLife Chief Executive Officer Michel Khalaf on Glassdoor.com. Michel Khalaf has an approval rating of 89% among the company's employees.

Does MetLife have any subsidiaries?

MetLife subsidiaries include Versant Health, Willing, Logan Circle Partners, American Life Insurance Company, Safeguard Health Enterprises, Grand Bank N.A., General American Life Insurance Company, and more.

Who are MetLife's major shareholders?

Top institutional shareholders of MetLife include Bank of New York Mellon Corp (0.61%), Assenagon Asset Management S.A., AustralianSuper Pty Ltd (0.29%) and Swedbank AB (0.26%). Insiders that own company stock include Steven J Goulart, Ramy Tadros, Marlene Debel, Bill Pappas, Susan M Podlogar, Jeh C Johnson and Michel Khalaf.
View institutional ownership trends
.

How do I buy shares of MetLife?

Shares of MET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of MetLife own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MetLife investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), General Electric (GE), International Business Machines (IBM), Exxon Mobil (XOM) and Intel (INTC).

This page (NYSE:MET) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners